← Leaderboards
David A Cheresh
Scripps Research Institute
$37,188,318
Attributed
$38,214,337
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$38,214,337 · 17
By mechanism
R01$19,562,145 · 7
R35$6,542,006 · 1
R37$6,290,895 · 1
P01$5,441,891 · 4
R21$339,900 · 1
R13$37,500 · 3
Top collaborators
- Mark Onaitis5 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- Martin Friedlander$49,465,428
- David D Schlaepfer$17,083,110
Others in their field
Top investigators on “Integrins”
- Timothy A Springer · Boston Children'S Hospital$50,095,849
- Mark Howard Ginsberg · University Of California, San Diego$28,221,483
- Martin A. Schwartz · Yale University$23,274,443
- M. Amin Arnaout · Massachusetts General Hospital$23,064,887
- Edward Franklin Plow · Cleveland Clinic Foundation$22,902,830
- Jun Qin · Cleveland Clinic Foundation$22,797,066
Research focus
IntegrinsAngiogenesisTumorPathway InteractionsNeoplastic CellNeoplasm MetastasisIn VivoMediatingResponseSignal TransductionCellsMalignant NeoplasmsBaseGrowth FactorEndothelial CellsSignal PathwayIn VitroTumor GrowthPreventMolecularReceptorTumor ProgressionLeadPrograms
Grant awards (113)
Attacking stress tolerance in cancer$900,275
R35 · FY2024 · CA · contact PI
Attacking stress tolerance in cancer$882,960
R35 · FY2023 · CA · contact PI
Attacking stress tolerance in cancer$928,703
R35 · FY2022 · CA · contact PI
Exploiting KRAS addiction for lung cancer therapy$407,210
R01 · FY2022 · CA · contact PI
Attacking stress tolerance in cancer$109,951
R35 · FY2022 · CA · contact PI
Attacking stress tolerance in cancer$767,436
R35 · FY2021 · CA · contact PI
Exploiting KRAS addiction for lung cancer therapy$415,519
R01 · FY2021 · CA · contact PI
Attacking stress tolerance in cancer$112,194
R35 · FY2021 · CA · contact PI
Attacking stress tolerance in cancer$945,158
R35 · FY2020 · CA · contact PI
Exploiting KRAS addiction for lung cancer therapy$414,424
R01 · FY2020 · CA · contact PI
Attacking stress tolerance in cancer$157,583
R35 · FY2020 · CA · contact PI
Attacking stress tolerance in cancer$111,898
R35 · FY2020 · CA · contact PI
Attacking stress tolerance in cancer$916,317
R35 · FY2019 · CA · contact PI
Exploiting KRAS addiction for lung cancer therapy$401,777
R01 · FY2019 · CA · contact PI
Attacking stress tolerance in cancer$709,531
R35 · FY2018 · CA · contact PI
CRAF-mediated vascular resistance to cancer therapies$465,256
R01 · FY2018 · CA · contact PI
Exploiting KRAS addiction for lung cancer therapy$413,109
R01 · FY2018 · CA · contact PI
CRAF-mediated vascular resistance to cancer therapies$465,256
R01 · FY2017 · CA · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$350,731
R01 · FY2017 · CA · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$105,777
R01 · FY2017 · CA · contact PI
CRAF-mediated vascular resistance to cancer therapies$465,256
R01 · FY2016 · CA · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$350,731
R01 · FY2016 · CA · contact PI
Targeting a non-canonical RAS-driven pathway in pancreatic cancer$321,625
R01 · FY2016 · CA · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$127,717
R01 · FY2016 · CA · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$89,970
R01 · FY2016 · CA · contact PI
CRAF-mediated vascular resistance to cancer therapies$465,256
R01 · FY2015 · CA · contact PI
MicroRNA regulation of RasGAP's during angiogenesis$381,687
R01 · FY2015 · HL · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$350,731
R01 · FY2015 · CA · contact PI
Targeting a non-canonical RAS-driven pathway in pancreatic cancer$321,625
R01 · FY2015 · CA · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$109,015
R01 · FY2015 · CA · contact PI
MicroRNA regulation of RasGAP's during angiogenesis$379,750
R01 · FY2014 · HL · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$340,209
R01 · FY2014 · CA · contact PI
Targeting a non-canonical RAS-driven pathway in pancreatic cancer$311,976
R01 · FY2014 · CA · contact PI
VEGF and PDGF in angiogenesis and tumor progression$430,440
R37 · FY2013 · CA · contact PI
MicroRNA regulation of RasGAP's during angiogenesis$368,900
R01 · FY2013 · HL · contact PI
Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors$350,731
R01 · FY2013 · CA · contact PI
Targeting a non-canonical RAS-driven pathway in pancreatic cancer$302,328
R01 · FY2013 · CA · contact PI
VEGF and PDGF in angiogenesis and tumor progression$459,245
R37 · FY2012 · CA · contact PI
MicroRNA regulation of RasGAP's during angiogenesis$387,188
R01 · FY2012 · HL · contact PI
Targeting a non-canonical RAS-driven pathway in pancreatic cancer$321,625
R01 · FY2012 · CA · contact PI
Role of Intergrin Signaling in Vascular Remodeling$306,384
P01 · FY2012 · HL · contact PI
VEGF and PDGF in angiogenesis and tumor progression$460,615
R37 · FY2011 · CA · contact PI
MicroRNA regulation of RasGAP's during angiogenesis$386,250
R01 · FY2011 · HL · contact PI
Regulation of metastasis by alpha V integrin and Src$349,600
R01 · FY2011 · CA · contact PI
Role of Intergrin Signaling in Vascular Remodeling$306,384
P01 · FY2011 · HL · contact PI
Regulation of cell invasion by apoptotic mechanisms$265,700
R01 · FY2011 · CA · contact PI
VEGF and PDGF in angiogenesis and tumor progression$476,313
R37 · FY2010 · CA · contact PI
Regulation of metastasis by alpha V integrin and Src$361,229
R01 · FY2010 · CA · contact PI
Role of Intergrin Signaling in Vascular Remodeling$306,384
P01 · FY2010 · HL · contact PI
Regulation of cell invasion by apoptotic mechanisms$273,918
R01 · FY2010 · CA · contact PI
Regulation of metastasis by alpha V integrin and Src$651,648
R01 · FY2009 · CA · contact PI
VEGF and PDGF in angiogenesis and tumor progression$468,441
R37 · FY2009 · CA · contact PI
NANOPARTICLE TARGETING TO TUMOR BLOOD VESSELS$445,019
P01 · FY2009 · CA · contact PI
Endothelial Barrier Function Regulation by VEGF$366,235
R01 · FY2009 · HL · contact PI
Regulation of metastasis by alpha V integrin and Src$354,968
R01 · FY2009 · CA · contact PI
Role of Intergrin Signaling in Vascular Remodeling$306,384
P01 · FY2009 · HL · contact PI
Regulation of cell invasion by apoptotic mechanisms$273,918
R01 · FY2009 · CA · contact PI
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$446,134
R37 · FY2008 · CA · contact PI
NANOPARTICLE TARGETING TO TUMOR BLOOD VESSELS$435,853
P01 · FY2008 · CA · contact PI
Small Molecules and Targeted Gene Delivery in Tumor Angiogenesis$366,261
P01 · FY2008 · CA · contact PI
Endothelial Barrier Function Regulation by VEGF$366,235
R01 · FY2008 · HL · contact PI
Regulation of metastasis by alpha V integrin and Src$345,453
R01 · FY2008 · CA · contact PI
Role of Intergrin Signaling in Vascular Remodeling$306,384
P01 · FY2008 · HL · contact PI
Regulation of cell invasion by apoptotic mechanisms$273,918
R01 · FY2008 · CA · contact PI
Identification of novel pancreatic cancer biomarkers$154,500
R21 · FY2008 · CA · contact PI
Animal Core$126,308
P01 · FY2008 · CA · contact PI
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$443,508
R37 · FY2007 · CA · contact PI
NANOPARTICLE TARGETING TO TUMOR BLOOD VESSELS$432,964
P01 · FY2007 · CA · contact PI
Endothelial Barrier Function Regulation by VEGF$366,235
R01 · FY2007 · HL · contact PI
Small Molecules and Targeted Gene Delivery in Tumor Angiogenesis$358,821
P01 · FY2007 · CA · contact PI
Regulation of metastasis by alpha V integrin and Src$342,397
R01 · FY2007 · CA · contact PI
Regulation of cell invasion by apoptotic mechanisms$273,918
R01 · FY2007 · CA · contact PI
Identification of novel pancreatic cancer biomarkers$185,400
R21 · FY2007 · CA · contact PI
Animal Core$124,117
P01 · FY2007 · CA · contact PI
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$445,057
R37 · FY2006 · CA · contact PI
Endothelial Barrier Function Regulation by VEGF$377,173
R01 · FY2006 · HL · contact PI
Cellular Responses to Vitronectin Binding Integrins$335,231
R01 · FY2006 · CA · contact PI
NANOPARTICLE TARGETING TO TUMOR BLOOD VESSELS$275,350
P01 · FY2006 · CA · contact PI
Vascular Survival Governed by Integrin Ligation State$268,258
R01 · FY2006 · CA · contact PI
Small Molecules and Gene Delivery in Tumor Angiogenesis$186,111
P01 · FY2006 · CA · contact PI
Animal Core$64,573
P01 · FY2006 · CA · contact PI
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$441,905
R37 · FY2005 · CA
Endothelial Barrier Function Regulation by VEGF$385,000
R01 · FY2005 · HL
NANOPARTICLE TARGETING TO TUMOR BLOOD VESSELS$268,256
P01 · FY2005 · CA
Cellular Responses to Vitronectin Binding Integrins$255,071
R01 · FY2005 · CA
Small Molecules and Gene Delivery in Tumor Angiogenesis$180,825
P01 · FY2005 · CA
Vascular Survival Governed by Integrin Ligation State$175,272
R01 · FY2005 · CA
Vascular Survival Governed by Integrin Ligation State$117,940
R01 · FY2005 · CA
Cellular Responses to Vitronectin Binding Integrins$103,940
R01 · FY2005 · CA
Animal Core$62,827
P01 · FY2005 · CA
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$523,206
R37 · FY2004 · CA
Cellular Responses to Vitronectin Binding Integrins$412,070
R01 · FY2004 · CA
Vascular Survival Governed by Integrin Ligation State$329,656
R01 · FY2004 · CA
Small Molecules and Gene Delivery in Tumor Angiogenesis$175,558
P01 · FY2004 · CA
Animal Core$60,996
P01 · FY2004 · CA
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$450,473
R37 · FY2003 · CA
Cellular Responses to Vitronectin Binding Integrins$412,070
R01 · FY2003 · CA
Vascular Survival Governed by Integrin Ligation State$329,656
R01 · FY2003 · CA
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$439,398
R37 · FY2002 · CA
Cellular Responses to Vitronectin Binding Integrins$412,070
R01 · FY2002 · CA
Vascular Survival Governed by Integrin Ligation State$329,656
R01 · FY2002 · CA
SMALL MOLECULE INHIBITORS OF TUMOR ANGIOGENESIS$197,079
P01 · FY2002 · CA
Biological Response to the Extracellular Matrix$7,500
R13 · FY2002 · CA
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$408,048
R37 · FY2001 · CA
CELLULAR RESPONSES TO A VITRONECTIN MATRIX$358,230
R01 · FY2001 · CA
CELLULAR RESPONSES TO A VITRONECTIN MATRIX$87,173
R01 · FY2001 · CA
Angiogenesis and Mircrocirculation Conference$20,000
R13 · FY2001 · CA
SMALL MOLECULE INHIBITORS OF TUMOR ANGIOGENESIS$0
P01 · FY2001 · CA
ALPHAV INTEGRINS AND TUMOR ANGIOGENESIS$398,112
R37 · FY2000 · CA
CELLULAR RESPONSES TO A VITRONECTIN MATRIX$349,505
R01 · FY2000 · CA
SMALL MOLECULE INHIBITORS OF TUMOR ANGIOGENESIS$149,053
P01 · FY2000 · CA
CELLULAR RESPONSES TO A VITRONECTIN MATRIX$87,173
R01 · FY2000 · CA
VASCULAR CELL BIOLOGY CONFERENCE$10,000
R13 · FY2000 · HL